If you've taken Paxlovid, you've probably worried about 'rebound'—that frustrating return of COVID-19 symptoms after you start feeling better. Doctors and patients have been asking whether the drug itself plays a role. To find out, researchers ran gold-standard clinical trials, giving some people Paxlovid and others a placebo, then watching to see what happened. The trials were conducted at sites in the United States and internationally. The study was designed to be rigorous, using a randomized, double-blind method so neither patients nor doctors knew who was getting the real drug. This is the kind of setup that can give us clear answers. However, the specific results from these trials—like how many people rebounded in each group or whether there was a difference—are not yet publicly reported. We also don't know key details about the people in the study or if there were any safety concerns. So, while this research tackles the right question head-on, we're still waiting for the crucial numbers that tell the full story.
Clinical trials examine COVID-19 rebound after nirmatrelvir/ritonavir versus placebo treatmentDoes the COVID-19 rebound risk change with or without Paxlovid treatment?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Seek full trial data on nirmatrelvir/ritonavir and COVID-19 rebound before clinical application.
A summary of randomized, double-blind clinical trials conducted at sites in the United States and internationally examined the occurrence of COVID-19 rebound following treatment. The intervention studied was nirmatrelvir/ritonavir, compared against a placebo. No specific results were reported for the primary outcome, secondary outcomes, or main results, including effect sizes, absolute numbers, or statistical measures. The population studied, sample size, and duration of follow-up were also not reported.
No safety or tolerability data were provided, including rates of adverse events, serious adverse events, or treatment discontinuations. The summary did not list specific methodological limitations of the trials. Information regarding funding sources or potential conflicts of interest was not reported.
Given the absence of reported results, the practice relevance of these trials for managing COVID-19 rebound cannot be determined. Clinicians should seek the full, peer-reviewed publication of these trials for detailed efficacy and safety data before drawing any conclusions about the relationship between nirmatrelvir/ritonavir and COVID-19 symptom rebound.
What this means for you:
Trials compared COVID rebound on Paxlovid vs. placebo, but the results aren't out yet. More on COVID
Nirmatrelvir/Ritonavir in Breast Milk: Low Infant Exposure in Lactating Women
Paxlovid levels low in breast milk, early study finds
This Phase 1 open-label study in 8 healthy lactating women found that nirmatrelvir/ritonavir concentrations in breast milk were consistently…
A small study finds that nirmatrelvir/ritonavir (Paxlovid) passes into breast milk at low levels, suggesting minimal infant exposure.
Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai
Your COVID Pill May Work Better—Or Worse—Than You Think
This cohort study of 48,243 SARS-CoV-2 BA.2-infected patients in Shanghai evaluated nirmatrelvir-ritonavir exposure.
How well your Paxlovid works depends heavily on your age and vaccination status.
Observational study finds low hospitalization and ED visit rates after Paxlovid treatment for COVID-19 in California
Did Paxlovid keep COVID patients in California out of the hospital?
An observational study of patients in California treated with Paxlovid for COVID-19 reported low rates of subsequent hospitalizations and em…
Paxlovid treatment for COVID-19 in California was linked to low rates of hospitalizations and emergency department visits, offering hope for…
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19
Paxlovid prescription linked to lower hospitalization risk in adults with COVID-19
An observational study of eligible US adults with COVID-19 found those prescribed Paxlovid were 51% less likely to be hospitalized.
Adults prescribed Paxlovid for COVID-19 were 51% less likely to be hospitalized compared to those who did not get the medication.
View Original Abstract ↓
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Linezolid Injection for Gram-Positive Infections Including Pneumonia and Skin Infections
FDA approves new antibiotic injection for serious bacterial infections
The FDA approved linezolid injection for nosocomial pneumonia, community-acquired pneumonia, complicated skin infections, and vancomycin-res…
The FDA approved linezolid injection for treating serious infections like pneumonia and skin infections caused by certain bacteria, includin…
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
Vancomycin Powder May Reduce Infections After High Risk Fractures
This meta-analysis of 3185 patients found that intrawound vancomycin powder significantly reduced postoperative infection rates (OR 0.59; 95…
A review of data suggests that using vancomycin powder in wounds may lower infection rates for patients with serious bone fractures.
Risk-adapted HLA delisting and imlifidase enable deceased-donor kidney transplantation for highly sensitized candidates
New guide helps transplant kidneys for hardest-to-match patients
This expert consensus provides a practical guideline for managing highly sensitized adult patients on the waitlist for deceased-donor kidney…
A new expert guide shows how to safely transplant kidneys into highly sensitized patients who have few options left.
Regenerative endodontic procedures may lead to unusual root morphology in immature teeth
Regenerative procedures can lead to unusual tooth root growth
This case report with literature review describes 2 immature teeth with pulp necrosis secondary to dens evaginatus treated with regenerative…
A new look at dental treatments shows that while some procedures save teeth, they can sometimes cause unexpected changes in how roots grow.
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.